News
And better still, healthy and growing dividend-paying stocks tend to increase their payouts over time. Pfizer's total annual ...
The tariff threat come just a few days after the White House sent letters to major drugmakers demanding slashed prices for US ...
Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...
21hon MSN
In the second quarter, Pfizer reported adjusted diluted earnings per share of $0.78 on revenue of nearly $14.7 billion. Both ...
Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...
Shares in the data-software company were up 7.8% Tuesday after it posted higher quarterly results and [boosted its annual ...
Pfizer's Albert Bourla told investors that major drugmakers are "ready to to roll up their sleeves" and build out more direct ...
Pfizer's strong EPS surprise streak and positive earnings revisions are encouraging, but patent cliff risks remain a major ...
Pfizer ( PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 guidance of between $61 to $64 ...
Second-quarter adjusted earnings came in at 78 cents a share on revenue of $14.7 billion, beating expectations.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback